Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Hopital Prive Clairval

Research site

France 317 Boulevard Du Redon, 13009 Marseille, France

  • 11 trials recruiting
  • Non-small cell lung cancer · Squamous cell carcinoma of head and neck · Hormone receptor positive HER2 negative breast cancer
  • Adult patients

About Specializations

Hopital Prive Clairval in Marseille, France specialises in clinical trials of conditions such as Non-small cell lung cancer, Squamous cell carcinoma of head and neck, Hormone receptor positive HER2 negative breast cancer, Hormone-refractory prostate cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Prostate Cancer Radiotherapy Research

The Hopital Prive Clairval Service d'oncologie radiotherapie in Marseille is conducting focused studies on high‑risk localized or locally advanced prostate cancer, evaluating whether adding apalutamide and a GnRH agonist to primary radiation therapy can improve metastasis‑free survival (MFS) as judged by central imaging review.

  • Combination systemic therapy with radiation
  • Metastasis‑free survival outcomes
  • Advanced imaging assessment by BICR

With nine investigators overseeing two active trials, the department emphasizes collaborative, patient‑centered research to enhance treatment effectiveness for prostate cancer patients in Europe.

Innovative Targeted Therapy Trials

A separate study at the same institution evaluates the safety and efficacy of JNJ56021927 (ARN509), a novel androgen‑receptor inhibitor, in patients receiving primary radiation for high‑risk prostate cancer, aiming to improve disease control and reduce side effects.

  • Novel androgen‑receptor inhibition
  • Safety profiling in a radiotherapy context
  • Potential for treatment de‑intensification

Conducted within a non‑commercial hospital setting, this research reflects the site's commitment to advancing therapeutic options and diagnostic precision for neoplastic diseases.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
317 Boulevard Du Redon13009 MarseilleFrance
Open in maps ↗
Recruiting now
11 trials
Conditions studied
15

More sites in MarseilleFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

24 clinical trials

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Neoplasm malignant

Recruiting

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Recruiting

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Merck Sharp & Dohme LLC

Squamous cell carcinoma of head and neck

Recruiting

Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Ivonescimab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Hormone-refractory prostate cancer+1

Recruiting

Study Comparing Ifinatamab Deruxtecan and Docetaxel for Patients with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

Squamous cell carcinoma of lung

Recruiting

Study of Pembrolizumab and MK-2870 for Patients with Metastatic Squamous Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Ventricular extrasystoles

Recruiting

Study of drug combination therapy in asymptomatic patients with frequent premature ventricular contractions and normal heart function to prevent left ventricular dysfunction

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bisoprolol Fumarate
  • Sponsor:Assistance Publique Hopitaux De Paris

Ischaemic stroke

Recruiting

Study on Colchicine and Ticagrelor for Preventing Ischemic Stroke in Patients with Atherosclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Assistance Publique Hopitaux De Paris

Non-small cell lung cancer

Recruiting

Study on Pembrolizumab and Chemotherapy with Radiation for Advanced Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Unicancer

Hormone-refractory prostate cancer

Recruiting

Study on Darolutamide and Radiation Therapy for Patients with Castration-Resistant Prostate Cancer and Oligometastases

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Unicancer

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Study evaluating the omission of exemestane, letrozole, anastrozole, and tamoxifen in postmenopausal women with low-risk early breast cancer.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Unicancer
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.